1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

VCs Raise Cash For New Deals; Five Biotechs Find Funding

 
• By Mandy Jackson

Venture capitalists raised $12bn for new US-based funds in the first quarter of 2016, including a handful of VC firms that invest in biotechnology, which is good news for early-stage drug developers that hope to close new funding rounds, like their peers at Entasis Therapeutics did recently.

Venture capitalists raised $12bn for new US-based funds in the first quarter of 2016, including a handful of VC firms that invest in biotechnology, which is good news for early-stage drug developers that hope to close new funding rounds, like their peers at Entasis Therapeutics did recently.

The National Venture Capital Association (NVCA) reported that 57 VC firms in the US raised new funds during the first quarter, which was a 17% decrease from the same period in 2015, but the dollar amount increased 59% year-over-year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.